formoterol fumarate


Summary: An ADRENERGIC BETA-2 RECEPTOR AGONIST with a prolonged duration of action. It is used to manage ASTHMA and in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Top Publications

  1. Nishikawa M, Mak J, Barnes P. Effect of short- and long-acting beta 2-adrenoceptor agonists on pulmonary beta 2-adrenoceptor expression in human lung. Eur J Pharmacol. 1996;318:123-9 pubmed
    ..Our data provide evidence for down-regulation of beta 2-adrenoceptor protein and mRNA after selective beta 2-adrenoceptor agonist treatment in human lung. ..
  2. Tan S, Hall I, Dewar J, Dow E, Lipworth B. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet. 1997;350:995-9 pubmed
    ..The homozygous Gly-16 form was significantly more prone to bronchodilator desensitisation than Arg 16, with the influence of Gly 16 dominating over any putative protective effects of Glu 27. ..
  3. Bochkov Y, Busse W, Brockman Schneider R, Evans M, Jarjour N, McCrae C, et al. Budesonide and formoterol effects on rhinovirus replication and epithelial cell cytokine responses. Respir Res. 2013;14:98 pubmed publisher
    ..These effects could potentially contribute to beneficial effects of budesonide/formoterol combination therapy in preventing RV-induced asthma exacerbations. ..
  4. Sauer R, Griff S, Blau A, Franke A, Mairinger T, Grah C. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia diagnosed by transbronchial lung cryobiopsy: a case report. J Med Case Rep. 2017;11:95 pubmed publisher
    ..This report and current literature indicate that transbronchial lung cryobiopsy can be used as a safe and practicable tool to obtain high quality biopsies of lung parenchyma in order to diagnose micronodular lesions of the lung. ..
  5. Jenkins C, Eriksson G, Bateman E, Reddel H, Sears M, Lindberg M, et al. Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment. BMC Pulm Med. 2017;17:65 pubmed publisher
  6. Rabe K. GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond. Expert Rev Clin Pharmacol. 2017;10:685-698 pubmed publisher
    ..This article describes the rationale for the development of the LAMA/LABA FDC of glycopyrrolate and formoterol fumarate, formulated by Co-Suspension™ Delivery Technology and delivered by MDI (GFF MDI)...
  7. Yan S, Shaw D, Yang L, Sandham D, Healy M, Reilly J, et al. Interactions between ?2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR. J Med Chem. 2017;60:6867-6879 pubmed publisher
    ..Our study elucidates at atomic level that the hydrophobicity and substitution geometry of lipophilic groups play important roles in compound-lipid interactions. ..
  8. Lin Y, Liao X, Fan L, Qu Y, Cheng D, Shi Y. Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D. PLoS ONE. 2017;12:e0183300 pubmed publisher
    ..A long-term treatment with Bud/Form alone or together with Tio can attenuate circulating CRP levels in COPD patients of group D, compared with Tio alone. ..
  9. Roewe J, Higer M, Riehl D, Gericke A, Radsak M, Bosmann M. Neuroendocrine Modulation of IL-27 in Macrophages. J Immunol. 2017;199:2503-2514 pubmed publisher
    ..7-fold increased by removal of the catecholamine-producing adrenal glands prior to endotoxic shock. These data suggest a novel role of the sympathetic neuroendocrine system for the modulation of IL-27-dependent acute inflammation. ..

More Information


  1. Sears M. The FDA-mandated trial of safety of long-acting beta-agonists in asthma: finality or futility?. Thorax. 2013;68:195-8 pubmed publisher
  2. D Urzo A, Rennard S, Kerwin E, Mergel V, Leselbaum A, Caracta C. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15:123 pubmed publisher of a fixed-dose combination (FDC) of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol fumarate, a long-acting β2-agonist, in patients with moderate to severe COPD are presented...
  3. Weisfeld L, Shu Y, Shah T. Bioequivalence of budesonide plus formoterol (BF) Spiromax® and BF Turbohaler® (with and without charcoal block) in healthy volunteers. Int J Clin Pharmacol Ther. 2015;53:593-602 pubmed publisher
    ..Single doses of BF Spiromax were well tolerated; the overall safety profile of BF Spiromax and BF Turbohaler was similar. ..
  4. Siddiqui S, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015;192:523-5 pubmed publisher
  5. Self T, Ellingson S. New Treatment Option for Chronic Obstructive Pulmonary Disease: Two Long-Acting Bronchodilators in a Single Metered-Dose Inhaler. Am J Med. 2017;130:1251-1254 pubmed publisher
    ..Glycopyrrolate is a long-acting muscarinic antagonist (LAMA), and formoterol fumarate is a long-acting beta2 agonist (LABA)...